Goldman Sachs Initiates Coverage On City Therapeutics with Early-Stage Biotech Rating

Benzinga · 2d ago
Goldman Sachs analyst Salveen Richter initiates coverage on City Therapeutics (NASDAQ:CTY) with a Early-Stage Biotech rating.